ALLG’s Blood Cancer Trial HD10/HD21 German Hodgkin Study Group Features on ABC Radio’s Health Report

ALLG HD10 trial leader, Professor Mark Hertzberg recently discussed the significant results of ALLG’s HD10 trial with Dr Norman Swan on ABC Radio’s Health Report.

The results of the international HD10 trial, in collaboration with the German Hodgkin Study Group (GHSG), showed superior results for younger patients with Hodgkin lymphoma through the delivery of less toxic, more targeted drugs that had fewer side effects and fewer treatment cycles for patients, and also preserved patient fertility. The HD10 trial results will set a new standard for treating this type of Hodgkin lymphoma globally.

Click here to listen to the full discussion.

ALLG continues to accelerate clinical trial research, partnering with lehttps://www.abc.net.au/listen/programs/healthreport/cancer-chemotherapy-hodgkin-lymphoma/104394192ading international cooperative groups to bring new and better blood cancer treatments to patients across Australia and New Zealand. To read more about our clinical trial research download a copy of the ALLG Research Report 2023 or support us through a variety of fundraising events. 

Professor Mark Hertzberg AM